FDA: evidentiary standards for drug development and approval - PubMed (original) (raw)

Review

FDA: evidentiary standards for drug development and approval

Russell Katz. NeuroRx. 2004 Jul.

Abstract

The United States Food and Drug Administration is charged with approving drug treatments that have been shown to be safe and effective. Relevant statutes and regulations provide a legal framework for establishing safety and effectiveness that is sufficiently flexible to ensure that appropriate scientific data are collected for specific treatments targeted to particular diseases. Nonetheless, all clinical trials proposed to establish effectiveness must incorporate common elements in order for the appropriate legal and scientific standards of drug approval to be met. This article will discuss the relevant laws and regulations pertaining to the current effectiveness standard and will discuss the most important clinical trial design elements currently considered acceptable for applications for treatments of neurologic and psychiatric illness.

PubMed Disclaimer

Cited by

Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
Becker RE, Greig NH. Becker RE, et al. J Clin Psychopharmacol. 2009 Feb;29(1):56-64. doi: 10.1097/JCP.0b013e318192e2fa. J Clin Psychopharmacol. 2009. PMID: 19142109 Free PMC article.
The Utility of Domain-Specific End Points in Acute Stroke Trials.
Cramer SC, Wolf SL, Saver JL, Johnston KC, Mocco J, Lansberg MG, Savitz SI, Liebeskind DS, Smith W, Wintermark M, Elm JJ, Khatri P, Broderick JP, Janis S; NIH StrokeNet Recovery and Rehabilitation Group and the Acute Stroke Group*. Cramer SC, et al. Stroke. 2021 Mar;52(3):1154-1161. doi: 10.1161/STROKEAHA.120.031939. Epub 2021 Feb 10. Stroke. 2021. PMID: 33563009 Free PMC article. Review.
US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
Morant AV, Vestergaard HT, Lassen AB, Navikas V. Morant AV, et al. Clin Transl Sci. 2020 Jul;13(4):652-664. doi: 10.1111/cts.12755. Epub 2020 Mar 3. Clin Transl Sci. 2020. PMID: 32043310 Free PMC article. Review.
Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.
Patel S, Steen D. Patel S, et al. J Thromb Thrombolysis. 2016 Feb;41(2):285-92. doi: 10.1007/s11239-015-1272-9. J Thromb Thrombolysis. 2016. PMID: 26374107 Review.
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D; Alzheimer's Disease Neuroimaging Initiative. Grill JD, et al. Neurobiol Aging. 2013 Jan;34(1):62-72. doi: 10.1016/j.neurobiolaging.2012.03.006. Epub 2012 Apr 13. Neurobiol Aging. 2013. PMID: 22503160 Free PMC article.

References

1. Guidance for industry—Providing evidence of effectiveness for human drug and biological products. U.S. Department of Health and Human Services, May 1998.
1. Royall R. Statistical evidence: a likelihood paradigm. In: Monographs on statistics and applied probability (Cox DR, Isham V, Keiding N, Reid N, Tong H, eds), p 31. London: Chapman & Hall, 1997.
1. Leber P. Hazards of inference: the active control investigation. Epilepsia 30 [Suppl 1]: S57–S63, 1989. - PubMed
1. Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 133: 455–463, 2000. - PubMed
1. Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133: 464–470, 2000. - PubMed

FDA: evidentiary standards for drug development and approval - PubMed (original) (raw)